Information Provided By: 
Fly News Breaks for May 27, 2015
ZSPH
May 27, 2015 | 08:08 EDT
Credit Suisse said ZS Phama remains a favorite name in a small cap space. Firm said upcoming catalysts include the filing of ZS-9 at the end of the quarter and public disclosure of any additional findings from the ongoing ZS-004 study included in the submission. The firm sees the hyperkalemia market as attractive with both drugs having significant potential. Credit Suisse raised ZS Pharma's price target to $67 from $58 and reiterates its Outperform rating on likely regulatory success.
News For ZSPH From the Last 2 Days
There are no results for your query ZSPH
